for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AbbVie Inc

ABBV.N

現在値

117.90USD

変化

1.03(+0.88%)

出来高

385,365

本日のレンジ

117.45

 - 

119.00

52週レンジ

101.55

 - 

121.53

∙ 約20分前の相場を表示しています。

適時開示

Abbvie Says Expands Immunology Portfolio In European Union With European Commission Approval Of Skyrizi

Nov 17 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE EXPANDS IMMUNOLOGY PORTFOLIO IN EUROPEAN UNION WITH EUROPEAN COMMISSION APPROVAL OF SKYRIZI.APPROVAL SUPPORTED BY DATA FROM TWO PHASE 3 STUDIES EVALUATING SKYRIZI IN PSORIATIC ARTHRITIS PATIENTS.

U.S. Food And Drug Administration Approves Vuity™ The First And Only Eye Drop To Treat Presbyopia (Age-Related Blurry Near Vision)

Oct 29 (Reuters) - Abbvie Inc <ABBV.N>::U.S. FOOD AND DRUG ADMINISTRATION APPROVES VUITY™ (PILOCARPINE HCI OPHTHALMIC SOLUTION) 1.25%, THE FIRST AND ONLY EYE DROP TO TREAT PRESBYOPIA (AGE-RELATED BLURRY NEAR VISION).

AbbVie Sees Q4 Adjusted Earnings Per Share Of $3.24 To $3.28

Oct 29 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE INC SAYS HAS NOT YET OBSERVED A SIGNIFICANT IMPACT TO USE OF RHEUMATOID ARTHRITIS DRUG RINVOQ AFTER FDA SAFETY COMMUNICATION.ABBVIE EXEC SAYS COULD SEE NEAR-TERM IMPACT TO NEW PATIENTS STARTS ON RINVOQ IF NEW LABEL RESTRICTS USE TO PATIENTS WHO DO NOT RESPOND TO TNF INHIBITORS.ABBVIE SEES Q4 SALES NEARING $15 BILLION.ABBVIE SEES Q4 ADJUSTED EARNINGS PER SHARE OF $3.24 TO $3.28.ABBVIE CEO SAYS NOT READY TO RE-CONFIRM ITS 2025 SALES GUIDANCE FOR RINVOQ YET, WILL WAIT FOR UPDATED LABEL.Further company coverage: ABBV.N. ((Reuters.Briefs@thomsonreuters.com;)).

Abbvie's Cariprazine Met Primary Endpoint In Phase 3 Study As An Adjunctive Treatment For Major Depressive Disorder

Oct 29 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE'S CARIPRAZINE (VRAYLAR®) MET PRIMARY ENDPOINT IN PHASE 3 STUDY AS AN ADJUNCTIVE TREATMENT FOR MAJOR DEPRESSIVE DISORDER.ABBVIE INC - STUDY 3111-302-001, CARIPRAZINE DEMONSTRATED NUMERICAL IMPROVEMENT IN DEPRESSIVE SYMPTOMS FROM BASELINE.ABBVIE INC - STUDY 3111-301-001, CARIPRAZINE (VRAYLAR®) MET ITS PRIMARY ENDPOINT DEMONSTRATING STATISTICALLY SIGNIFICANT CHANGE FROM BASELINE.ABBVIE INC - SAFETY DATA WERE CONSISTENT WITH ESTABLISHED SAFETY PROFILE OF CARIPRAZINE ACROSS INDICATIONS.ABBVIE INC - INTENDS TO SUBMIT A SNDA WITH FDA FOR EXPANDED USE OF CARIPRAZINE FOR ADJUNCTIVE TREATMENT OF MDD.

Abbvie Announces ABBV-951 Showed Improvement In Controlling Motor Fluctuations In Pivotal Phase 3 Trial

Oct 28 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE ANNOUNCES ABBV-951 (FOSLEVODOPA/FOSCARBIDOPA) SHOWED IMPROVEMENT IN CONTROLLING MOTOR FLUCTUATIONS COMPARED TO ORAL LEVODOPA/CARBIDOPA MEDICATION IN PIVOTAL PHASE 3 TRIAL IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE.ABBVIE INC - SYSTEMIC ADVERSE EVENTS WERE GENERALLY CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF LEVODOPA/CARBIDOPA MEDICATIONS.ABBVIE INC - INFUSION SITE ADVERSE EVENTS WERE MOSTLY NON-SERIOUS AND MILD OR MODERATE IN SEVERITY.ABBVIE - PATIENTS WHO GOT 24 HOURS/DAILY ABBV-951 SHOWED STATISTICALLY SIGNIFICANT INCREASES IN HOURS OF "ON" TIME WITHOUT TROUBLESOME DYSKINESIA.ABBVIE - PIVOTAL PHASE 3 STUDY OF CONTINUOUS, SUBCUTANEOUS INFUSION OF ABBV-951 MET ITS PRIMARY ENDPOINT IN A 12-WEEK STUDY.ABBVIE INC - DATA FROM HEAD-TO-HEAD SUPERIORITY STUDY WILL BE A KEY COMPONENT OF GLOBAL REGULATORY SUBMISSIONS.ABBVIE INC - SIGNIFICANT REDUCTION IN HOURS OF "OFF" TIME WAS ALSO OBSERVED IN STUDY.

Abbvie Receives CHMP Positive Opinion For Risankizumab For The Treatment Of Psoriatic Arthritis

Oct 15 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE RECEIVES CHMP POSITIVE OPINION FOR RISANKIZUMAB (SKYRIZI®) FOR THE TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS IN THE EUROPEAN UNION (EU).

Eurobio Scientific Receives USD 430,000 Milestone Payment From Allergan

Oct 6 (Reuters) - EUROBIO SCIENTIFIC SA <ALERS.PA>::EUROBIO SCIENTIFIC RECEIVES A $430,000 MILESTONE PAYMENT FROM ALLERGAN.TRANSITION TO CLINICAL STAGE OF A MOLECULE DERIVED FROM FORMER COLLABORATION.MILESTONE PAYMENT OF US $ 430,000 AS PART OF AN IND SUBMISSION TO US FDA FOR TRANSITION TO CLINICAL PHASE OF AGN-231868 MOLECULE IN TREATMENT OF DRY EYE SYNDROME.

AbbVie Says FDA Approves Qulipta, Developed For Preventive Treatment Of Migraine

Sept 28 (Reuters) - AbbVie Inc <ABBV.N>::FDA APPROVES QULIPTA™ (ATOGEPANT), THE FIRST AND ONLY ORAL CGRP RECEPTOR ANTAGONIST SPECIFICALLY DEVELOPED FOR THE PREVENTIVE TREATMENT OF MIGRAINE.ABBVIE - QULIPTA DEMONSTRATED STATISTICALLY SIGNIFICANT, CLINICALLY MEANINGFUL RAPID, CONTINUOUS REDUCTIONS IN MEAN MONTHLY MIGRAINE DAYS IN ADULTS.ABBVIE INC - TRIAL SHOWED WHEN TAKING QULIPTA, MAJORITY OF PATIENTS EXPERIENCED BETWEEN A 50-100% REDUCTION IN MONTHLY MIGRAINE DAYS ACROSS 12 WEEKS.

Alvotech Says FDA Defers Action on Application For Proposed Humira Biosimilar

Sept 20 (Reuters) - Alvotech::ALVOTECH PROVIDES UPDATE ON FDA ACTION REGARDING AVT02, PROPOSED HIGH-CONCENTRATION BIOSIMILAR TO HUMIRA® (ADALIMUMAB).ALVOTECH: FDA DEFERRING ACTION ON APPLICATION FOR AVT02, PROPOSED BIOSIMILAR TO HUMIRA, UNTIL FACILITY ASSESSMENTS CAN BE COMPLETED.ALVOTECH: CONTINUES TO WORK WITH FDA TO COORDINATE REQUIRED INSPECTION(S) IN SAFE AND ADEQUATE MANNER.

Abbvie Inc Submits Regulatory Application To FDA For RISANKIZUMAB-RZAA (SKYRIZI)

Sept 20 (Reuters) - Abbvie Inc <ABBV.N>::ABBVIE SUBMITS REGULATORY APPLICATION TO FDA FOR RISANKIZUMAB-RZAA (SKYRIZI®) FOR THE TREATMENT OF PATIENTS 16 YEARS AND OLDER WITH MODERATE TO SEVERE CROHN'S DISEASE.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up